Your browser doesn't support javascript.
loading
Changes in SUMO-modified proteins in Epstein-Barr virus infection identifies reciprocal regulation of TRIM24/28/33 complexes and the lytic switch BZLF1.
De La Cruz-Herrera, Carlos F; Tatham, Michael H; Siddiqi, Umama Z; Shire, Kathy; Marcon, Edyta; Greenblatt, Jack F; Hay, Ronald T; Frappier, Lori.
Afiliação
  • De La Cruz-Herrera CF; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Tatham MH; Division of Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
  • Siddiqi UZ; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Shire K; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Marcon E; Donnelly Centre, University of Toronto, Toronto, Canada.
  • Greenblatt JF; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Hay RT; Donnelly Centre, University of Toronto, Toronto, Canada.
  • Frappier L; Division of Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
PLoS Pathog ; 19(7): e1011477, 2023 07.
Article em En | MEDLINE | ID: mdl-37410772
SUMO modifications regulate the function of many proteins and are important in controlling herpesvirus infections. We performed a site-specific proteomic analysis of SUMO1- and SUMO2-modified proteins in Epstein-Barr virus (EBV) latent and lytic infection to identify proteins that change in SUMO modification status in response to EBV reactivation. Major changes were identified in all three components of the TRIM24/TRIM28/TRIM33 complex, with TRIM24 being rapidly degraded and TRIM33 being phosphorylated and SUMOylated in response to EBV lytic infection. Further experiments revealed TRIM24 and TRIM33 repress expression of the EBV BZLF1 lytic switch gene, suppressing EBV reactivation. However, BZLF1 was shown to interact with TRIM24 and TRIM33, resulting in disruption of TRIM24/TRIM28/TRIM33 complexes, degradation of TRIM24 and modification followed by degradation of TRIM33. Therefore, we have identified TRIM24 and TRIM33 as cellular antiviral defence factors against EBV lytic infection and established the mechanism by which BZLF1 disables this defence.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Vírus Epstein-Barr Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Vírus Epstein-Barr Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article